Literature DB >> 19918062

HIV-1 Gag-specific immunity induced by a lentivector-based vaccine directed to dendritic cells.

Bingbing Dai1, Lili Yang, Haiguang Yang, Biliang Hu, David Baltimore, Pin Wang.   

Abstract

Lentivectors (LVs) have attracted considerable interest for their potential as a vaccine delivery vehicle. In this study, we evaluate in mice a dendritic cell (DC)-directed LV system encoding the Gag protein of human immunodeficiency virus (HIV) (LV-Gag) as a potential vaccine for inducing an anti-HIV immune response. The DC-directed specificity is achieved through pseudotyping the vector with an engineered Sindbis virus glycoprotein capable of selectively binding to the DC-SIGN protein. A single immunization by this vector induces a durable HIV Gag-specific immune response. We investigated the antigen-specific immunity and T-cell memory generated by a prime/boost vaccine regimen delivered by either successive LV-Gag injections or a DNA prime/LV-Gag boost protocol. We found that both prime/boost regimens significantly enhance cellular and humoral immune responses. Importantly, a heterologous DNA prime/LV-Gag boost regimen results in superior Gag-specific T-cell responses as compared with a DNA prime/adenovector boost immunization. It induces not only a higher magnitude response, as measured by Gag-specific tetramer analysis and intracellular IFN-gamma staining, but also a better quality of response evidenced by a wider mix of cytokines produced by the Gag-specific CD8(+) and CD4(+) T cells. A boosting immunization with LV-Gag also generates T cells reactive to a broader range of Gag-derived epitopes. These results demonstrate that this DC-directed LV immunization is a potent modality for eliciting anti-HIV immune responses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19918062      PMCID: PMC2777969          DOI: 10.1073/pnas.0911742106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  47 in total

1.  Polyfunctional CD4+ T-cell induction in neutralizing antibody-triggered control of simian immunodeficiency virus infection.

Authors:  Takuya Yamamoto; Nami Iwamoto; Hiroyuki Yamamoto; Tetsuo Tsukamoto; Tetsuya Kuwano; Akiko Takeda; Miki Kawada; Yasuko Tsunetsugu-Yokota; Tetsuro Matano
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

Review 2.  New insights on adenovirus as vaccine vectors.

Authors:  Marcio O Lasaro; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2009-06-09       Impact factor: 11.454

3.  Engineered lentivector targeting of dendritic cells for in vivo immunization.

Authors:  Lili Yang; Haiguang Yang; Kendra Rideout; Taehoon Cho; Kye Il Joo; Leslie Ziegler; Abigail Elliot; Anthony Walls; Dongzi Yu; David Baltimore; Pin Wang
Journal:  Nat Biotechnol       Date:  2008-02-24       Impact factor: 54.908

Review 4.  Dendritic cell-based human immunodeficiency virus vaccine.

Authors:  C R Rinaldo
Journal:  J Intern Med       Date:  2009-01       Impact factor: 8.989

5.  DNA gag/adenovirus type 5 (Ad5) gag and Ad5 gag/Ad5 gag vaccines induce distinct T-cell response profiles.

Authors:  Kara S Cox; James H Clair; Michael T Prokop; Kara J Sykes; Sheri A Dubey; John W Shiver; Michael N Robertson; Danilo R Casimiro
Journal:  J Virol       Date:  2008-06-04       Impact factor: 5.103

Review 6.  Challenges in the development of an HIV-1 vaccine.

Authors:  Dan H Barouch
Journal:  Nature       Date:  2008-10-02       Impact factor: 49.962

7.  HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis.

Authors:  M Juliana McElrath; Stephen C De Rosa; Zoe Moodie; Sheri Dubey; Lisa Kierstead; Holly Janes; Olivier D Defawe; Donald K Carter; John Hural; Rama Akondy; Susan P Buchbinder; Michael N Robertson; Devan V Mehrotra; Steven G Self; Lawrence Corey; John W Shiver; Danilo R Casimiro
Journal:  Lancet       Date:  2008-11-13       Impact factor: 79.321

8.  Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.

Authors:  Susan P Buchbinder; Devan V Mehrotra; Ann Duerr; Daniel W Fitzgerald; Robin Mogg; David Li; Peter B Gilbert; Javier R Lama; Michael Marmor; Carlos Del Rio; M Juliana McElrath; Danilo R Casimiro; Keith M Gottesdiener; Jeffrey A Chodakewitz; Lawrence Corey; Michael N Robertson
Journal:  Lancet       Date:  2008-11-13       Impact factor: 79.321

9.  The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine.

Authors:  Christine Trumpfheller; Marina Caskey; Godwin Nchinda; Maria Paula Longhi; Olga Mizenina; Yaoxing Huang; Sarah J Schlesinger; Marco Colonna; Ralph M Steinman
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-06       Impact factor: 11.205

10.  Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys.

Authors:  Jinyan Liu; Kara L O'Brien; Diana M Lynch; Nathaniel L Simmons; Annalena La Porte; Ambryice M Riggs; Peter Abbink; Rory T Coffey; Lauren E Grandpre; Michael S Seaman; Gary Landucci; Donald N Forthal; David C Montefiori; Angela Carville; Keith G Mansfield; Menzo J Havenga; Maria G Pau; Jaap Goudsmit; Dan H Barouch
Journal:  Nature       Date:  2008-11-09       Impact factor: 49.962

View more
  24 in total

Review 1.  Immunization delivered by lentiviral vectors for cancer and infectious diseases.

Authors:  Biliang Hu; April Tai; Pin Wang
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

2.  Dendritic cells infected by recombinant rabies virus vaccine vector expressing HIV-1 Gag are immunogenic even in the presence of vector-specific immunity.

Authors:  Celestine N Wanjalla; Elizabeth J Faul; Emily A Gomme; Matthias J Schnell
Journal:  Vaccine       Date:  2010-08-20       Impact factor: 3.641

3.  A TLR4 agonist synergizes with dendritic cell-directed lentiviral vectors for inducing antigen-specific immune responses.

Authors:  Liang Xiao; Jocelyn Kim; Matthew Lim; Bingbing Dai; Lili Yang; Steven G Reed; David Baltimore; Pin Wang
Journal:  Vaccine       Date:  2012-02-05       Impact factor: 3.641

4.  Differential immune responses mediated by adenovirus- and lentivirus-transduced DCs in a HER-2/neu overexpressing tumor model.

Authors:  T C Felizardo; J C M Wang; R A J McGray; C Evelegh; D E Spaner; D H Fowler; J L Bramson; J A Medin
Journal:  Gene Ther       Date:  2011-04-14       Impact factor: 5.250

5.  A tetracycline-regulated cell line produces high-titer lentiviral vectors that specifically target dendritic cells.

Authors:  Paul D Bryson; Chupei Zhang; Chi-Lin Lee; Pin Wang
Journal:  J Vis Exp       Date:  2013-06-19       Impact factor: 1.355

6.  Dendritic cell-targeted lentiviral vector immunization uses pseudotransduction and DNA-mediated STING and cGAS activation.

Authors:  Jocelyn T Kim; Yarong Liu; Rajan P Kulkarni; Kevin K Lee; Bingbing Dai; Geoffrey Lovely; Yong Ouyang; Pin Wang; Lili Yang; David Baltimore
Journal:  Sci Immunol       Date:  2017-07-21

7.  An engineered novel lentivector specifically transducing dendritic cells and eliciting robust HBV-specific CTL response by upregulating autophagy in T cells.

Authors:  Siyuan Ma; Xiaohua Chen; Quanhui Tan; Dan Li; Shenglan Dai; Shanshan Wu; Yongsheng Yu; Guoqing Zang; Zhenghao Tang
Journal:  Cell Cycle       Date:  2018-07-18       Impact factor: 4.534

8.  Potentiating functional antigen-specific CD8⁺ T cell immunity by a novel PD1 isoform-based fusion DNA vaccine.

Authors:  Jingying Zhou; Allen Kl Cheung; Henggui Liu; Zhiwu Tan; Xian Tang; Yuanxi Kang; Yanhua Du; Haibo Wang; Li Liu; Zhiwei Chen
Journal:  Mol Ther       Date:  2013-04-16       Impact factor: 11.454

9.  PD1-based DNA vaccine amplifies HIV-1 GAG-specific CD8+ T cells in mice.

Authors:  Jingying Zhou; Allen K L Cheung; Zhiwu Tan; Haibo Wang; Wenbo Yu; Yanhua Du; Yuanxi Kang; Xiaofan Lu; Li Liu; Kwok-Yung Yuen; Zhiwei Chen
Journal:  J Clin Invest       Date:  2013-05-01       Impact factor: 14.808

10.  Vaccines delivered by integration-deficient lentiviral vectors targeting dendritic cells induces strong antigen-specific immunity.

Authors:  Biliang Hu; Bingbing Dai; Pin Wang
Journal:  Vaccine       Date:  2010-08-13       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.